Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (vol 393, pg 143, 2019)

被引：0
|
作者：
Cahn, P.
Madero, J. S.
Arribas, J. R.
机构：
来源：
LANCET | 2019年 / 393卷 / 10167期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [1] Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
    Cahn, Pedro
    Sierra Madero, Juan
    Ramon Arribas, Jose
    Antinori, Andrea
    Ortiz, Roberto
    Clarke, Amanda E.
    Hung, Chien-Ching
    Rockstroh, Jurgen K.
    Girard, Pierre-Marie
    Sievers, Jorg
    Man, Choy
    Currie, Alexander
    Underwood, Mark
    Tenorio, Allan R.
    Pappa, Keith
    Wynne, Brian
    Fettiplace, Anna
    Gartland, Martin
    Aboud, Michael
    Smith, Kimberly
    LANCET, 2019, 393 (10167): : 143 - 155
  • [2] Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
    Lisi Deng
    Chunna Li
    Ping Chen
    Xiaoqing Luo
    Xinchun Zheng
    Lanlan Zhou
    Yi Zhou
    Jinyu Xia
    Zhongsi Hong
    BMC Infectious Diseases, 22
  • [3] Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
    Deng, Lisi
    Li, Chunna
    Chen, Ping
    Luo, Xiaoqing
    Zheng, Xinchun
    Zhou, Lanlan
    Zhou, Yi
    Xia, Jinyu
    Hong, Zhongsi
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [4] Dolutegravir plus Lamivudine vs. Dolutegravir plus Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies
    Underwood, Mark
    Urbaityte, Rimgaile
    Wang, Ruolan
    Horton, Joe
    Oyee, James
    Wynne, Brian
    Fox, Dainielle
    Jones, Bryn
    Man, Choy
    Sievers, Joerg
    VIRUSES-BASEL, 2024, 16 (03):
  • [5] Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
    Cahn, Pedro
    Madero, Juan Sierra
    Arribas, Jose R.
    Antinori, Andrea
    Ortiz, Roberto
    Clarke, Amanda E.
    Hung, Chien-Ching
    Rockstroh, Juergen K.
    Girard, Pierre-Marie
    Sievers, Jorg
    Man, Choy Y.
    Urbaityte, Rimgaile
    Brandon, Daisy J.
    Underwood, Mark
    Tenorio, Allan R.
    Pappa, Keith A.
    Wynne, Brian
    Gartland, Martin
    Aboud, Michael
    van Wyk, Jean
    Smith, Kimberly Y.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (03) : 310 - 318
  • [6] Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials (vol 83, pg 310, 2020)
    Cahn, P.
    Madero, J. S.
    Arribas, J. R.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 84 (03) : E21 - E21
  • [7] Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
    Venter, Willem D. F.
    Sokhela, Simiso
    Simmons, Bryony
    Moorhouse, Michelle
    Fairlie, Lee
    Mashabane, Nkuli
    Serenata, Celicia
    Akpomiemie, Godspower
    Masenya, Masebole
    Qavi, Ambar
    Chandiwana, Nomathemba
    McCann, Kaitlyn
    Norris, Shane
    Chersich, Matthew
    Maartens, Gary
    Lalla-Edward, Samanta
    Vos, Alinda
    Clayden, Polly
    Abrams, Elaine
    Arulappan, Natasha
    Hill, Andrew
    LANCET HIV, 2020, 7 (10): : E666 - E676
  • [8] Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
    Raffi, Francois
    Rachlis, Anita
    Stellbrink, Hans-Juergen
    Hardy, W. David
    Torti, Carlo
    Orkin, Chloe
    Bloch, Mark
    Podzamczer, Daniel
    Pokrovsky, Vadim
    Pulido, Federico
    Almond, Steve
    Margolis, David
    Brennan, Clare
    Min, Sherene
    LANCET, 2013, 381 (9868): : 735 - 743
  • [9] Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    Wohl, David A.
    Yazdanpanah, Yazdan
    Baumgarten, Axel
    Clarke, Amanda
    Thompson, Melanie A.
    Brinson, Cynthia
    Hagins, Debbie
    Ramgopal, Moti N.
    Antinori, Andrea
    Wei, Xuelian
    Acosta, Rima
    Collins, Sean E.
    Brainard, Diana
    Martin, Hal
    LANCET HIV, 2019, 6 (06): : E355 - E363
  • [10] Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (vol 381, pg 735, 2013)
    Raffi, F.
    Rachlis, A.
    Stellbrink, H-J
    LANCET, 2014, 384 (9946): : 856 - 856
12345